Faced with stress and brain fog, columnist Juliet Taylor thought that staying on top of things would keep her husband's ALS ...

The first patient has been dosed in a Phase 2 clinical trial testing RAG-17 in people with ALS who carry mutations in the ...

Clene is scheduled to meet with the FDA in the coming months to discuss new data for CNM-Au8, its experimental oral therapy ...

The first healthy volunteers have been dosed in an early clinical trial testing NRG5051, a disease-modifying therapy for ALS ...

Reflecting on past journal entries reminds columnist Kristin Neva that life as an ALS caregiver is always a mix of good and hard times.

The FDA granted fast track status to VectorY’s VTx-002, an antibody gene therapy targeting TDP-43 protein aggregates in ALS.

The ALS Association is urging members of Congress to take action to address issues with instability in leadership at the NIH.

Shionogi plans to acquire global rights to Radicava and Radicava ORS for ALS through a new U.S. business formed by Tanabe ...

Health Canada has cleared the way for ALS patients in that nation to join the ongoing ALSTARS U.S. trial testing therapy ...

Even after 15 years with her husband's ALS, losing caregivers still brings about grief and stress for columnist Kristin Neva.

Aperture Therapeutics is advancing APRTX-003, an RNA-based antisense therapy targeting MMP9, as a potential ALS treatment.

With ALS, columnist Dagmar Munn says she must focus her mind and make deliberate choices when decision-making fatigue sets in.